Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.200
-0.030 (-1.35%)
Mar 13, 2025, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Employees
As of December 31, 2023, Inhibikase Therapeutics had 9 total employees, including 8 full-time and 1 part-time employees. The number of employees increased by 2 or 28.57% compared to the previous year.
Employees
9
Change (1Y)
2
Growth (1Y)
28.57%
Revenue / Employee
$0
Profits / Employee
-$2,173,917
Market Cap
152.60M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9 | 2 | 28.57% |
Dec 31, 2022 | 7 | 0 | - |
Dec 31, 2021 | 7 | 4 | 133.33% |
Dec 31, 2020 | 3 | - | - |
IKT News
- 17 days ago - Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewsWire
- 23 days ago - Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth - GlobeNewsWire
- 6 weeks ago - Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study - Reuters
- 4 months ago - Inhibikase: Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha
- 4 months ago - Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension - GlobeNewsWire
- 7 months ago - Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript - Seeking Alpha